Axogen (AXGN) Long-Term Debt Repayments (2017 - 2026)

Axogen (AXGN) recorded quarterly Long-Term Debt Repayments of $48.6 million in Q1 2026, up 485750.0% quarter-over-quarter from $10000.0 in Q4 2018.

Axogen (AXGN) Long-Term Debt Repayments (2017 - 2026) Analysis & Trends

Axogen's Long-Term Debt Repayments history runs 3 years deep, the most recent figure standing at $48.6 million for Q1 2026.

In Q1 2026, Long-Term Debt Repayments changed N/A year-over-year to $48.6 million; the TTM figure through Mar 2026 stood at $48.6 million (changed N/A YoY), while the FY2020 annual figure was $7.8 million, changed N/A from the prior year.
Long-Term Debt Repayments was $48.6 million for Q1 2026 at Axogen, up from $10000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $48.6 million in Q1 2026 to a low of $48.6 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	1.42 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	1.00 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	-
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	-
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	-
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	-
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	-
10	Axogen	2.22 Bn	2.12 Bn	46.19 Mn	48.59 Mn

Download Data